Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations.

Lung cancer (Amsterdam, Netherlands) - 1 Jun 2018

Ricciuti Biagio, Baglivo Sara, Ludovini Vienna, Sidoni Angelo, Metro Giulio, Brambilla Marta, Siggillino Annamaria, Reda Maria Sole, Rebonato Alberto, Maiettini Daniele, Chiari Rita

Abstract excerpt

Although epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) mutations were thought to be mutually exclusive in patients with non-small cell lung cancer (NSCLC), the development of high sensitive large-scale mutation analysis, has increasingly shown that activating EGFR mutations occasionally coexist with other dominant genetic alterations. Herein, we discuss the case...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins p21(ras)

Share to Remission Induction

Share to Survival Analysis

Source

Identifiers

PMID: 29748019
DOI: 10.1016/j.lungcan.2018.04.002

Genes

EGFR
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations.PMID 29748019Read ↗

The clinicopathologic characteristics and outcomes of uncommon KRAS mutations in patients with non-small cell lung cancer.Semantic proximity Read ↗

Trametinib in the treatment of advanced lung adenocarcinoma with KRAS G12D mutation: a case report and literature reviewSemantic proximity Read ↗

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.Semantic proximity Read ↗

Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review.Semantic proximity Read ↗

Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance.Semantic proximity Read ↗

Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancerSemantic proximity Read ↗

[Clinical Analysis of 107 NSCLC Patients Harboring KRAS Mutation].Semantic proximity Read ↗

Concomitant driver mutations in advanced EGFR -mutated non-small-cell lung cancer and their impact on erlotinib treatmentSemantic proximity Read ↗

[A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib].Semantic proximity Read ↗

Furmonertinib Activity in NSCLC Harboring EGFR L858R and ERBB2 S310F Co-Mutations: A Case Report With Literature ReviewSemantic proximity Read ↗

A Case of Non-Small Cell Lung Cancer with Mutually Exclusive EGFR and KRAS MutationsSemantic proximity Read ↗

New monoallelic combination of KRAS gene mutations in codons 12 and 13 in the lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.